RxDoctor Payments Data

Jeffrey Martin, MD

Nephrology · Lancaster, PANPI 1558313205

Payments from drug & device makers

$4,058in general payments, 2019–2025

Across 25 payments — averaging $162.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
  • Vifor Pharma, Inc.$325
  • AstraZeneca$306
  • Otsuka America Pharmaceutical, Inc.$243
  • Urovant Sciences Inc$203
  • Amgen$134
  • plus $274 from 6 others

What the payments were for

  • Consulting fees$2,74968%
  • Speaking & faculty fees$2005%
  • Food & beverage$97024%
  • Education$1393%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,058 in reported general payments places this provider in the 75th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$166,080
Medicare patients
553
Services billed
1,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin27$38,633
FarxigaDapagliflozin Propanediol16$21,745
EliquisApixaban12$9,068
Calcium Acetate64$4,300
Cinacalcet Hcl20$3,875
Nifedipine ErNifedipine111$3,663
Clonidine26$3,574
Eplerenone46$3,355
Torsemide146$2,785
Carvedilol235$2,525
Mycophenolate Mofetil21$2,398
Losartan Potassium201$1,999
BystolicNebivolol Hcl12$1,899
Doxazosin Mesylate87$1,865
Metoprolol Succinate119$1,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$306$21,74516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →